No Data
Rhythm Pharmaceuticals Presents Data On Patients With Acquired Or Congenital Hypothalamic Obesity (N=35) Treated With Setmelanotide For Up To Nine Months In French Early-Access Program
Citigroup Maintains Buy on Akero Therapeutics, Lowers Price Target to $78
Akero Therapeutics Analyst Ratings
U.S. stock market close: The Nasdaq surged over 4%, Chinese concept stocks performed even stronger, and the Golden Dragon Index outperformed the Large Cap.
① High-level economic and trade talks between China and the U.S. exceeded expectations, boosting U.S. stocks; ② Both the S&P and Nasdaq hit new closing highs since March 3; ③ NVIDIA rose over 5%, with its Market Cap returning to above 3 trillion; ④ Trump: Will investigate pharmaceutical companies if necessary.
Akero Therapeutics GAAP EPS of -$0.90 Beats by $0.12
Akero Therapeutics Q1 2025 EPS $(0.90) Beats $(0.99) Estimate, Cash, Cash Equivalents, And Short- And Long-term Marketable Securities As Of March 31, 2025, Were $1.128B, Will Be Sufficient To Fund Its Current Operating Plan Into 2028
